MSRB2 and Parkinson disease: Taken together: (i) aggregation of Parkin is associated with MetO, (ii) MsrB2, which reduces MetO, interacts with Parkin, (iii) MsrB2 overexpression is able to reduce Parkin aggregation, (iv) the presence of human mutations at Met 192 is associated with Parkinson's disease (Meng et al, 2011), and (v) platelet Parkin knockout reduces mitophagy leading to increased platelet apoptosis and thrombosis (Lee et al, 2016), all suggest and support oxidative stress‐induced MetO at position 192 on Parkin serving as a “brake” on platelet mitophagy.